Genmab — Oktober 2020
-
New trial: A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma https://clinicaltrials.gov/ct2/show/NCT04586426
-
Any opinion about the liver tox in GEN1046?
-
Thank you, there were some doubts from Nordea, but very impressive on efficiacy on those heavily pretreated patients they apparently concluded
-
Yes
-
I have not seen the note myself, but 6 patients had dose limiting tox incl elevated liver enzymes they write
-
Liver tox have in the past been a problem and hindernis for 4-1BB drugs, and therefore this has to be monitored closely they conclude
-
I have seen it, thank you.
-
A bit dissapointing that there haven‘t been any comments from oncologists so far
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind